5-MeO-DMT Fumarate Crystallization via Low-Temperature Cooling

Solution Overview

Problem

Existing methods fail to produce a crystalline form of 5-methoxy-N,N-dimethyltryptamine fumarate effectively, with attempts resulting in a suspension rather than a crystalline solution, and it is unclear how deuterated analogues would behave in terms of polymorphs.

Innovation Solution

A method involving dissolving 5-methoxy-N,N-dimethyltryptamine in ethanol at low temperatures (15° C to 75° C), contacting it with fumaric acid, stirring, and cooling to collect crystalline fumarate salts, which surprisingly yields at least three distinct polymorphs of 5-MeO-DMT fumarate and its deuterated analogues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If the method of WO 2021/089873 (heating at 70-100°C) is used to produce crystalline fumarate salts, then crystalline DMT fumarate can be obtained, but 5-MeO-DMT fumarate does not form a solution and fails to produce crystals

Engineering Contradiction:
Core Design Contradiction:
Manufacturing precisionVSReliability

Solution Approach 1:

The patent changes the temperature parameter from high (70-100°C) to low (15-75°C) to enable crystallization of 5-MeO-DMT fumarate. This parameter change resolves the contradiction by finding optimal conditions where 5-MeO-DMT fumarate successfully forms crystals, unlike the previous method which failed completely for this compound.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Instead of following the conventional high-temperature approach that worked for DMT but failed for 5-MeO-DMT, the patent inverts the temperature approach by using low temperatures (15-75°C). This inversion of the temperature parameter successfully produces crystalline 5-MeO-DMT fumarate where the conventional method failed.

Inventive Principle:
Principle #13The other way round (Inversion)

2Adaptability or versatility

If deuterated analogues are produced using conventional methods, then a single polymorph is expected, but three distinct polymorphs are actually obtained

Engineering Contradiction:
Core Design Contradiction:
Adaptability or versatilityVSManufacturing precision

Solution Approach 1:

The low temperature parameter range (15-75°C) enables the formation of multiple polymorphs that would not form at higher temperatures. This parameter change increases polymorph diversity while maintaining manufacturing precision through controlled crystallization conditions.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent utilizes phase transitions during cooling to generate multiple polymorphic forms. By controlling the temperature reduction from 75°C to 15°C, different crystalline phases are stabilized, resulting in three distinct polymorphs with characteristic PXRD patterns.

Inventive Principle:
Principle #36Phase transitions

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method provides crystalline fumarate salts of 5-MeO-DMT with excellent yield and stability, characterized by specific PXRD patterns, and demonstrates therapeutic potential for psychiatric and neurological disorders.

Implementation Method 1

Dissolving a freebase of the 5-methoxy-N,N-dimethyltryptamine compound in ethanol at a temperature of about 15° C. to about 75° C. to form an ethanolic solution; contacting the ethanolic solution of the 5-methoxy-N,N-dimethyltryptamine compound with fumaric acid; cooling the mixture to between about 5° C. and about 0° C.; and filtering the mixture to collect the crystalline fumarate salt

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Implementation Method 2

cooling the mixture to between about 5° C. and about 0° C.

Methodology Applied
Scientific EffectCooling: Cooling

Implementation Method 3

cooling the mixture to between about 5° C. and about 0° C.; and filtering the mixture to collect the crystalline fumarate salt

Methodology Applied
Scientific EffectPrecipitation: Precipitation

Data Source

PatentUS11697638B25-methoxy-N,N-dimethyltryptamine crystalline forms
Publication Date: 2023.07.11
  • US11697638B2 patent drawing
  • US11697638B2 patent drawing
  • US11697638B2 patent drawing

AI summary

Described herein are crystalline fumarate salts having a Formula I, pharmaceutical formulations comprising the same, methods for their production, and uses thereof, Formula I comprising:wherein each R1 is independently selected from protium and deuterium; each R2 is independently selected from protium and deuterium; each R3 is independently selected from protium and deuterium; and each R4 is independently selected from protium and deuterium; and wherein the compound has a PXRD pattern comprising characteristic peaks at 19.2±0.2 and 24.7±0.2 degrees 2-theta.